Kisqali 600 MG daily dose UU 63S
Ended Awarded Last action
- Contract number
- SPE2DR26FWHU8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,280
Award facts
- Contract value 100% obligated
- $12,280.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12.28K delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 22, 2026, for the supply of Kisqali 600 mg daily dose pharmaceutical products, with an ultimate completion date of February 12, 2026. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract is a child delivery order executed under a larger Indefinite Delivery Contract vehicle with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical supply mechanism for military healthcare programs.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (formerly AmerisourceBergen), is a major pharmaceutical distributor serving federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and military treatment facilities worldwide. The company's extensive portfolio under the DLA prime vendor contract encompasses brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies across multiple therapeutic domains. This specific delivery order for Kisqali, a breast cancer treatment medication, exemplifies the contractor's capability to supply critical specialty pharmaceutical products to support military healthcare systems on a firm fixed-price basis.
Quick answers
Who was awarded contract SPE2DR26FWHU8?
SPE2DR26FWHU8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FWHU8 worth?
The government has obligated $12,280 on SPE2DR26FWHU8.
Is contract SPE2DR26FWHU8 an order under another contract?
Yes. SPE2DR26FWHU8 is a delivery order under SPE2DR25D3009, an indefinite delivery contract.
Was contract SPE2DR26FWHU8 competed?
The extent of competition for SPE2DR26FWHU8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award